Home
This site is intended for healthcare professionals

Alcohol Use Disorders (AUD) - Practice in Action: Micro masterclass: implementing global principles locally

Share

Description

This activity is supported by an independent educational grant from Lilly. This online educational programme has been designed for healthcare professionals worldwide, except in the United Kingdom.

This CME-accredited micro masterclass on alcohol use disorders (AUD) explores how evidence-based guidance can be applied in local practice. Using a clinical case, discover practical approaches to diagnosis, treatment planning, monitoring and coordinated care, while identifying ways to overcome local service barriers.

Session Highlights

  • Identify and diagnose AUD: Apply validated screening tools and document diagnoses effectively.
  • Individualise treatment: Align treatment goals and medication choices with patient needs and local guidance.
  • Coordinate care: Strengthen referral pathways, monitoring and escalation between services.
  • Apply evidence locally: Identify practical changes to improve care despite resource and system constraints.

Target Audience:

Healthcare professionals involved in the screening, diagnosis, treatment and ongoing management of alcohol use disorders, including primary care clinicians, psychiatrists, mental health professionals and addiction specialists.

Faculty

Dr. Néstor Szerman, MD

Complutense University of Madrid, Spain, is internationally recognised for his expertise in addictions and dual disorders. His career has been dedicated to advancing research and treatment in this field. He currently practises at the Complutense University of Madrid, Spain, and he was the Founding President of the Spanish Society of Dual Disorders (2005-2016) and is President of the World Association on Dual Disorders (WADD) (2024-2027), Chair of the WPA Section on Dual Disorders, President of the Dual Disorders Foundation (since 2016) and Co-Director “catedra patologia dual” Francisco de Vitoria University, Spain.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Néstor Szerman, MD faculty for this educational activity, has the following relevant financial relationships: Consultant and/or Advisor Gedeon Richter/Recordati, Lundbeck and Eli Lilly

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-391-H01-P

Type of Activity: Knowledge

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until September 25th 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This continuing education activity is active starting November 17th 2026, and will expire on September 25th 2027.

Estimated time to complete this activity: 30 Minutes

Learning objectives

After completing this educational program HCP's should be better able to:

• Implement validated screening guidelines, tools, and DSM-5-TR diagnostic criteria within clinical workflows to accurately identify and document AUD across the full severity spectrum (mild, moderate, severe) in ≥ 80% of case-based exercises.

• Formulate patient-centered AUD treatment plans that align with individualized goals (reduction or abstinence) and appropriately initiate evidence-based pharmacologic and behavioral treatment strategies without universally requiring prior abstinence in ≥ 75% of simulated clinical scenarios.

• Execute coordinated, multidisciplinary care pathways that integrate pharmacotherapy, psychotherapy, peer support, and structured follow-up, clearly defining team roles, referral pathways, and accountability processes in ≥ 80% of team-based application exercises.

• Evaluate and apply emerging clinical research and updated guideline recommendations to optimize AUD management workflows and reduce delays in adoption of evidence-based practices in ≥ 70% of implementation-planning exercises.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

In this presentation today, we are going to cover one of the topics that in some way is, we could say, an orphan in the field of psychiatry and mental health, which is alcohol use disorder in our patients. Over the next 30 minutes, we are going to try to identify what type of patient we have to treat. The diagnosis for it, how we plan the treatment, how we agree on the treatment goals for these patients, how we coordinate therapeutic continuity, and finally, how we integrate evidence, and also, of course, the limitations of the system. Because sometimes the same patient and the same evidence change from one region to another, from one place to another. We are going to follow and review this whole topic of alcohol use disorder through a typical patient, whom we will call Elena, and whom we will follow on her therapeutic journey. Elena is a 48 year old woman who lives with a partner, works full time, and was referred to our clinic for affective symptoms, that is anxiety and depression. In this case, although it was not the reason for consultation, alcohol use disorder was assessed. The alcohol use disorder was identified. I will talk more about it in a moment, and the goal was agreed with her, which is not strictly the treatment itself. Pod dichotomously, it would be whether she preferred to reduce consumption, which she didn't propose, or total abstinence. After 3 months, we found that the patient had reduced her alcohol consumption, but not enough to achieve the goals she set for herself, and her mood had not improved. In fact, she had missed some of the follow-up appointments we had given her, and the family, in this case, her partner, asked, who is in charge of this? The questions, therefore, at this point are who would be responsible for the care and referral of this patient. What can be prescribed, what can be done, and how should it be supervised, and how do referrals work in practice? It is common for the response to be incomplete. What matters is what the system does for this patient. It is important to bear in mind that we must evaluate alcohol use disorder in our patients, even if it is not the main reason for consumption. You are all familiar with the audit C. With 3 questions in 3 minutes, we can get an assessment, evaluation, not a diagnosis. We get a view of our patients' risky consumption. In this case, Elena scored 7 points. There are other measures, of course, such as standard drink verification, which changes from country to country and is also used in research and clinical trials. We will see that once risky consumption is identified, as Audit C identifies for us, we should have a diagnosis, and for that, we must use the standard instruments in our psychiatric clinical practice, such as the DSM-5. You all know the 11 criteria in the DSM-5TR for alcohol use disorder. I would like to remind you that criteria 10 and 11 are for those people, those patients who present physiological dependence, that is tolerance and withdrawal. This only affects a tiny minority of our patients with alcohol use disorder, and is not necessary to diagnose alcohol use disorder. Of the 11 criteria, someone who meets 2 or 3 criteria could already be diagnosed with mild alcohol use disorder. Someone who meets 45, or 6 criteria would have a diagnosis of moderate alcohol use disorder, and more than 6 criteria would be severe, which may, I stress, or may not include physiological dependence. As we see in our patient, enough criteria were met to have a diagnosis of moderate alcohol use disorder. Therefore, it is important for our patients that we ask, screen, evaluate, classify, and document. What does that mean? Who asks about alcohol consumption in the psychiatric interview? Do we do it? How do we screen for the existence of a problem with alcohol consumption? How do we evaluate it? How do we diagnose it? Therefore, if we classify the diagnosis, whether it is mild, moderate, or severe, and how we record it in our clinical history, Because in this case, it is very important that it is recorded in order to move forward with the next decisions we have to make. Therefore, I would like to ask you, when a patient comes to your service with depression, anxiety, or sleep problems, how often do you screen for consumption of alcohol using a validated tool? The possible answers are always, often, sometimes, rarely or never. Well, we have a moment to vote, and then we will continue. Of course, we live in an environment in the West where alcohol consumption is integrated into our culture. In Mediterranean countries, sometimes very clearly, everyone sometimes drinks alcohol daily, a beer or a glass of wine. That can pose problems for us when identifying the disorder. Patients minimize or reject any evaluation of this issue if it isn't severe, sometimes saying, Doctor, I drink what everyone drinks, I drink what I've always drunk. Despite this, we must use standardized tools to obtain a more appropriate diagnosis. Therefore, once we identify that this problem exists, we also have to agree with the patient on the objective and what we intend to achieve once this diagnosis is made. Therefore, Elena tells us, our patient tells us that she wants to reduce consumption, that she would like not to give it up completely, but to have a normalized life in relation to alcohol. What most limits agreement on this reduction goal in your setting? Guidelines or prescribing limits, our team's attitude towards reduction, perhaps patient expectations, or our capacity to monitor. We have a moment to vote, and then we will continue. This would be dichotomously two possible approaches that do not necessarily have to clash. Purists who say, let's fight for an alcohol-free society, or a pragmatic view that for many patients, perhaps the majority, means reducing the problems associated with alcohol consumption, once diagnosed. Treatment must be, as always, biological, psychological, and social, but pay attention in that order biological, psychological, and social. We have approved medications for alcohol use disorder up to this moment. The two most common are naltrexone and nalmphine. They are two opioid antagonists with different mechanisms of action. I personally prefer nalmphine, but it faces difficulties and prescribing barriers. It requires medical inspection authorization, and the pill boxes dispensed are very small. A camprosate is not widely available for use. And finally, we have disulfiram, one of the oldest medications on the market. It often requires great determination from the patient to live a life distant from alcohol. In that case, disulfiram would protect the patient and support their decision to live, function, and be alcohol-free. There are other off-label, unapproved medications that our colleagues sometimes use, and that we prescribe for patients with alcohol use disorder, but these are the treatments approved by regulatory agencies. Once we decide that the therapeutic goal is reduction rather than abstinence, we need to know what that entails. Whether alcohol consumption should be measured and how often. We assess craving, the intense urge to consume. We assess our patient's mood. In this case, Elena had affective problems, depression, anxiety, insomnia. We evaluate the impact of her progress on her daily functioning, in her job, relationships, and daily activities, and how the treatment is working, who measures it, and how often. The therapeutic objective is obviously useful if we measure and review it. Therefore, who would realistically be responsible for Elena's follow-up in your professional environment? The psychiatrist, the addiction specialist or service, the primary care clinician, or no one in particular. You have a moment to vote. It is important to keep in mind that patients with alcohol use disorder will present other mental disorders, which sometimes increase as the severity of the alcohol use disorder increases.